Research in Your Backyard

Developing Cures, Creating Jobs



Dots show locations of clinical trials in the state.

PHARMACEUTICAL CLINICAL TRIALS IN MINNESOTA

PhRMA
RESEARCH • PROGRESS • HOPE

Executive Summary

Clinical Trials in Minnesota

- Biopharmaceutical research companies have conducted more than 2,900 clinical trials of new medicines since 1999 in collaboration with the state's local research institutions, including the **Clinical Research Institute** in Minneapolis and Plymouth, **Twin Cities Clinical Research/ Prism Clinical Research** in Brooklyn Center, **Prism Clinical Research** in St. Paul, **MAPS Applied Research Center** in Edina, **Minnesota Diet Research Center/Frestedt Inc.** in St. Louis Park, **Mercy Hospital** in Coon Rapids, **St. Mary's Duluth Clinic** in Duluth, **St. Cloud Hospital** in St. Cloud, **St. Paul's Heart Clinic** in St. Paul, the **University of Minnesota School of Medicine** in Minneapolis and the **Mayo Clinic** in Rochester.

- The trials have been aimed at a wide array of diseases and medical conditions, ranging from the most debilitating chronic diseases, including cancer, pain, heart disease, obesity and diabetes, to bothersome allergies, sinusitis, chronic obstructive pulmonary disease (COPD), migraine headaches, pneumonia and rare diseases affecting small patient populations.

- With so much clinical trial activity in the state, widespread public awareness of trials is a challenge which led to the formation of a unique coalition—the **Minnesota Clinical Research Alliance (MCRA)**.

"Advancements in medicine would not be possible without individuals willing to volunteer their time to participate in clinical studies. The Minnesota Clinical Research Association (MCRA) is a collaboration of Minnesota based research institutions and professionals who are committed to objectively informing the general public to the benefits and risks involved in clinical research far beyond international and domestic regulations. MCRA members believe that a fully informed participant is critical to successful clinical research outcomes."

—Jeff Cosgrove, President
Prism Clinical Research

- MCRA provides important clinical research education at a time when it is a challenge for biopharmaceutical and device companies and local research collaborators to recruit volunteers, and patients often don't know about trials of new drugs.

- Clinical trials in Minnesota have not only been good for patients, but also the state's economy and the advancement of science and overall patient health care.

> ***"Clinical research brings together teams of hundreds of healthcare professionals, patients, suppliers, statisticians, monitors and other partners to carefully review how potential new treatments work in real people. MCRA makes sure we stay focused on the patient while creating awareness of the unique research environment Minnesota has to offer. We bring new clinical trials to patients every day, and we love what we do, because it makes a difference."***
>
> —Sarah Moeller, M.S., President
> The Greenlight Group, LLC

MCRA—Making Patients Aware of Clinical Trials and Their Importance

- The MCRA was launched two years ago to educate the public, elected officials and the media about the importance of clinical research to patients and the health care system and the state's economy.
- A collaborative effort of key elements of the Minnesota medical research community, MCRA is dedicated to explaining research all over the state "in understandable terms."
- Alliance presentations, media meetings, opinion pieces and materials stress the patient safety protections built into the clinical trial system and how trials of new drugs and medical devices are helping to advance science and, ultimately, overall patient health care.
- MCRA also stresses the economic impact of clinical research on a state that, in 2010, had 11 percent of all of the clinical trials conducted in the United States. Minnesota also boasts the second highest number of medical technology jobs in the nation.
- In the words of Dr. Gary Berman of the Clinical Research Institute, an Alliance partner, the MCRA has chosen "to put collaboration above competition in the best interests of patients. We can all accomplish more by working together to promote the strength of research in Minnesota."
- Many of the partners in the MCRA are heavily involved in the clinical testing of new products in the state for a range of diseases, including infectious and respiratory conditions, cancer, asthma, migraine headaches, allergies and others.
- Some of the partners provide clinical research expertise and sophisticated equipment that enable biopharmaceutical companies and their local collaborators to conduct trials.
- To learn about the companies that make up the Alliance, visit the website *www.mnclinicalresearch.org*.
- The website address of each partner is provided and at each site, explanations in easy-to-read language are provided about the important work of each organization. On some sites, information is provided on trials recruiting patients, making them potentially important to some disease sufferers and their health care providers.
- MCRA partners include Agility Research, Courante Oncology, the Clinical Research Institute, Frestedt Inc., MAPS Applied Research Center (MARC), MEDTOX Laboratories, the Minnesota Center for Obesity, Metabolism & Endocrinology (MNCOME), Minnesota Diet Research Center (MDRC), Minnesota Gastroenterology, Prism Clinical Research, The Greenlight Group, LLC, and Twin Cities Clinical Research/Prism Clinical Research.
- The BioBusiness Alliance of Minnesota and LifeScience Alley, another bioscience support organization, collaborate with the Alliance as affiliates.

About Clinical Trials and Why the MCRA Mission is Important

- According to a 2007 survey by CenterWatch, a company that publishes information on clinical trials, patient enrollment problems delay more than 70 percent of clinical trials from one to six months. Fewer than five percent of cancer patients participate in clinical trials. The educational efforts of the MCRA help to create more awareness and understanding of trials of new drugs, devices and food that gives Minnesota patients the opportunity to discuss becoming trial volunteers with their doctors.

- Delays in clinical trials mean drug development takes longer, costs more and patients have to wait for treatments they may desperately need.

- Clinical trials are conducted to help evaluate the safety and effectiveness of new products and generate the data the Food and Drug Administration needs to approve new treatments.

- Clinical tests of new drugs are conducted in three pre-approval phases and account for an average of seven of the 10 to 15 years required today to research and develop a new treatment. Trials involve thousands of volunteer patients and the generation of large volumes—sometimes tens of thousands of pages—of technical and scientific data.

- Clinical trials account for 45 to 75 percent of the average $1.2 billion cost of developing one new biotechnology medicine and that's an important statistic considering that biopharmaceutical companies frequently hire local research institutions, such as members of the MCRA and the University of Minnesota School of Medicine, to conduct the tests.

- For some patients who are still seeking treatments that are best for them, clinical trials can be a potential therapeutic option to discuss with health care providers.

- Many medicines, devices and other products that have been clinically tested in Minnesota and other states are cutting-edge technologies with a strong potential to advance science and patient health care.

- Biotech medicines may be derived from novel biological processes that feature cells, genes and other living organisms. With biotechnology, we have the strong potential to develop safer and more effective treatments and we are improving our ability to predict and prevent diseases.

- From the standpoint of patient safety, clinical trials are rigorously reviewed and approved by an Institutional Review Board (IRB)—an independent committee of health care providers, social workers, statisticians, local patient advocates and others—to ensure trials protect patient rights, and safety and are ethically conducted. Many IRBs exist right here in the state of Minnesota.

The Importance of Clinical Trials

Since 1999, more than 2,900 clinical trials have been conducted or are being conducted in Minnesota. The clinical trials have addressed many of the leading causes of death in the United States and in Minnesota, such as cancer, heart disease and diabetes. And they've targeted debilitating diseases that cause severe pain, such as psoriasis, rheumatoid arthritis, and epilepsy. Of these trials, 419 are either not yet recruiting or are just now seeking Minnesota patients. The 419 trials are being conducted at more than 550 sites in Minnesota.

All of these conditions contribute to health care spending in Minnesota.

- In 2010, health care spending in Minnesota was $37.7 billion—for hospital care, physician services, long-term care, prescription drugs, dental services and other health care costs.
- Per capita spending on health care in Minnesota was $7,090 in 2010, compared to the national average of $7,900.
- In 2010, Minnesota was home to 11 percent of all clinical trials in the United States.

Clinical Trials in Minnesota	
All Clinical Trials	**Clinical Trials Still Recruiting**
2,945	419

Source: www.clinicaltrials.gov
Note: Search criteria = Minnesota, United States; Phase 0, 1, 2, 3; industry only. Search performed 11/27/2013.

Economic Benefits of Clinical Trials in Minnesota

- Biopharmaceutical research companies have been a source of jobs, tax revenue and research spending in Minnesota.
- A study by Battelle Technology Partnership Practice found that in 2011 the industry supported more than 31,000 jobs throughout the state.
- Wages and benefits for employees whose jobs were supported by the biopharmaceutical sector resulted in about $127 million in federal taxation and $23 million in state and local taxes.
- Biopharmaceutical research companies supported the generation of $7.4 billion in economic activity in the state two years ago, including the direct economic output of the sector itself, the output of

the sector's vendors and suppliers and the output generated by the buying power of its workforce.

- Company employees in Minnesota include life sciences researchers, management executives, office and administrative support workers, production workers, engineers, architects, computer and math experts and sales representatives. Biopharmaceutical companies, in 2011, also supported the jobs of their vendors and suppliers, including construction and IT firms. And the employees of biopharmaceutical companies help to support local restaurants, day care centers and other community businesses.

Clinical Trials in Minnesota Communities

Location	Arth	Ca	Crd	Crohn's	Dia	Ep	ID	K/L	Mental	Psor	Resp	Other
Brooklyn Ctr	—	—	1	—	—	—	—	—	—	—	—	—
Chaska	2	—	2	1	—	—	—	—	—	—	—	1
Duluth	1	3	6	—	2	—	2	1	—	—	—	—
Eagan	10	—	—	—	1	—	—	—	—	—	1	1
Edina	3	6	5	—	1	—	2	—	—	1	5	5
Fridley	—	2	1	—	—	—	—	—	—	10	6	1
Golden Valley	—	—	—	—	—	4	—	—	—	—	—	—
Minneapolis	—	62	42	5	5	6	20	14	2	1	31	8
Plymouth	—	—	—	7	—	1	1	1	—	—	6	1
Rochester	2	77	15	16	—	4	2	14	1	—	12	5
St. Louis Park	—	21	3	—	—	1	—	—	—	—	—	—
St. Cloud	—	3	10	—	2	—	1	—	—	—	—	—
St. Paul	—	4	8	3	4	6	4	5	1	—	—	1

Source: www.clinicaltrials.gov
Note: Search criteria = Minnesota, United States; Phase 0, 1, 2, 3; industry only. Search performed 11/27/2013. See Appendix for detailed information about these clinical trials. ***Disease columns will not match totals in the Appendix because some clinical trials are recruiting in more than one city. This list of cities and towns is representative and not a complete list of where clinical trials are taking place in Minnesota.***

Clinical Trials in Minnesota

Clinical tests of new medicines are a vitally important part of the drug development and approval process—they account for 45 to 75 percent of the $1.2 billion average cost of developing a new drug and are conducted to determine the safety and effectiveness of that treatment in patients.

Some trials are also conducted to compare existing treatments and some are done to explore whether a drug is appropriate for a different patient population, such as children. Still others are conducted to find ways to make existing approved drugs more effective and easier to use with fewer side effects.

It's essential that trials be conducted properly so that clinicians and drug reviewers can develop accurate assessments of the efficacy and safety of medicines when used by patients. The FDA is a vigilant regulatory agency and its pharmaceutical review officers are effective in detecting flawed information.

Questionable or confusing data can lead to lengthy delays in product approval or outright FDA rejection of a new drug.

Biopharmaceutical research companies are looking for the best physicians and research institutions to help design and conduct their clinical trials to determine whether a medicine is safe and effective. Side effects must be carefully documented and a determination made as to whether they occur too often and are dangerous.

> ***"Clinical research provides access to new and promising treatments for patients while connecting them with first rate care. At CRI, we are committed to helping patients today and in the future through cutting-edge research. We are passionate about the work we do and participating in MCRA allows us to draw attention to researchers across Minnesota who wake up every day with the goal of improving the lives of other Minnesotans."***
>
> —Gary D. Berman, M.D.
> Clinical Research Institute

Clinical tests involve three phases, thousands of volunteer patients, and are often conducted at multiple sites around the country.

In Minnesota, biopharmaceutical companies are providing funds to have trials conducted at the state's well-respected medical schools, hospitals and clinical research organizations. According to *U.S. News and World Report*, **Mayo Medical School** ranked 27th and the **University of Minnesota Medical School** ranked 38th among this year's top 100 research-oriented medical schools in the United States.

Clinical Trials in Minnesota	
Disease	**Clinical Trials Still Recruiting**
Arthritis	15
Cancer	154
Cardiovascular Disease	58
Crohn's Disease/Ulcerative Colitis/ Gastrointestinal	24
Diabetes	10
Epilepsy/Neurological Disorders	21
Infectious Diseases	31
Kidney and Liver Disorders	32
Mental Illnesses	4
Psoriasis/Skin Disorders	11
Respiratory Disorders	35
Other Diseases	26

Source: www.clinicaltrials.gov
Note: Search criteria = Minnesota, United States; Phase 0, 1, 2, 3; industry only. Search performed 11/27/2013. See Appendix for detailed information about these clinical trials. ***Some clinical trials appear in more than one disease category.***

Arthritis, the most common cause of disability in the United States, affects about 50 million adults and 300,000 children, according to the Arthritis Foundation. In Minnesota, according to the Minnesota Department of Health (MDH), approximately 995,000 adults or 26 percent of Minnesota adults have arthritis. Arthritis consists of more than 100 different diseases or conditions affecting the joints, bones, muscles and other connective tissues.

There are 15 clinical trials recruiting patients in Minnesota for arthritis, specifically rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Trials are being conducted at **St. Paul Rheumatology** in St. Paul and the **Mayo Clinic** in Rochester, among others.

Cancer, the second leading cause of death in the United States, now afflicts nearly 14 million Americans, according to the National Cancer Institute. In Minnesota, more than 28,000 new cancer cases will be diagnosed this year and 9,610 victims in the state will die, according to the American Cancer Society.

Currently, 154 clinical trials of new cancer medicines are recruiting patients in Minnesota. Biopharmaceutical companies are collaborating on the tests with such institutions as the **Mayo Clinical Cancer Center** in Rochester, the **Virginia Piper Cancer Institute at Abbott Northwestern Hospital** and the **Masonic Cancer Center at the University of Minnesota** in Minneapolis, the **Park Nicollet Fravenshuh Cancer Center** in St. Louis Park, **St. Luke's Hospital Association** in Duluth, and the **Regions Hospital Cancer Care Center** in St. Paul.

Cardiovascular Disease is the leading cause of death in the United States and in Minnesota. According to the American Heart Association, more than 82 million Americans are affected by these diseases. In Minnesota, in 2011, more than 10,000 residents died from some form of cardiovascular disease, according to the Minnesota Department of Health.

Currently, 58 cardiovascular disease clinical tests are seeking patients in Minnesota. The trials are being conducted at the **University of Minnesota** and the **Minneapolis Heart Institute at Abbott Northwestern Hospital** in Minneapolis, **MAPS Applied Research Center (MARC)** in Edina, **Minnesota Center for Obesity, Metabolism and Endocrinology (MNCOME)** in Eagan, **Prism Clinical Research and the St. Joseph Hospital** in St. Paul, **CentraCare Heart and Vascular Center** in St. Cloud and the **Park Nicollet Institute** in St. Louis Park.

Crohn's Disease and Ulcerative Colitis (inflammatory bowel disease) affect 1.4 million Americans and are evenly split between the two, according to the Crohn's and Colitis Foundation of America. Other gastrointestinal disease medicine trials that are still recruiting patients in Minnesota are targeting GERD, chronic idiopathic constipation, celiac disease, irritable bowel syndrome and erosive esophagitis.

Currently, 24 clinical tests are seeking patients in Minnesota for Crohn's disease, ulcerative colitis, irritable bowel syndrome and other gastrointestinal disorders. The trials are being conducted at **Minnesota Gastroenterology (MNGASTRO)** in Plymouth, the **Mayo Clinic** in Rochester and **Minnesota Colon & Rectal Surgery Associates** in Minneapolis.

Diabetes affects more than 25 million Americans—more than 8 percent of the U.S. population—including 7 million people who are unaware they have the disease. About 290,000 adults have been diagnosed with diabetes and as many as 1.4 million adults have prediabetes in Minnesota, according to the Minnesota Department of Health.

Currently, 10 diabetes clinical tests are seeking patients in Minnesota. The trials are being conducted at the **Twin Cities Clinical Research/Prism Clinical Research** in Brooklyn Center, the **International Diabetes Center/ Maya Clinic** in Minneapolis, **Prism Clinical Research** in St. Paul, **Minnesota Center for Obesity, Metabolism and Endocrinology (MNCOME)** in Eagan, and **Radiant Research** in Edina.

Epilepsy affects nearly 3 million Americans, according to the Epilepsy Foundation. The Epilepsy Foundation Minnesota estimates that one in 26 people will develop the disease at some point in their life. Other neurologic disorders targeted by clinical trials that are still recruiting include migraine, amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis, spinal cord injury and muscular dystrophies.

Currently, there are 21 clinical trials recruiting patients in Minnesota for neurologic disorders. The trials are underway at the **Mayo Clinic** in Rochester, the **University of Minnesota** in Minneapolis, **MAPS Applied Research Center (MARC)** in Edina, **Prism Clinical Research** and **Gilette Children's Specialty Healthcare** in St. Paul and the **Minneapolis Clinic of Neurology** in Golden Valley.

Infectious Diseases, both newly emerging and re-emerging, caused more than 62,000 deaths in the United States in 2010, according to the U.S. Centers for Disease Control and Prevention. In 2011, 708 Minnesota residents died from infectious and parasitic diseases, according to the Minnesota Department of Health.

There are 31 clinical trials recruiting patients in Minnesota for infectious diseases, including, aspergillosis, herpes zoster, influenza, meningococcal disease, onychomycosis, candidiasis, HIV infection, urinary tract infections, intra-abdominal infections, Hepatitis B, Hepatitis C, *Clostridium difficle* infections, and athlete's foot (tinea pedis). Trials are being conducted at **Minnesota Gastroenterology (MNGASTRO)** in St. Paul, the **University of Minnesota** and the **Hennepin County Medical Center** in Minneapolis, and the **Mayo Clinic** in Rochester.

Kidney and Liver Diseases are among the 15 leading causes of death in the United States and Minnesota. Clinical trials recruiting patients in Minnesota are aimed at polycystic kidney disease, end stage renal disease, liver failure, hepatic veno-occlusive disease, cirrhosis, chronic kidney disease, liver fibrosis, among others.

There are 32 clinical trials for kidney and liver diseases recruiting patients in Minnesota. Trials are underway at **DaVita Clinical Research** and the **University of Minnesota** in Minneapolis, **Children's Hospitals and Clinics of Minnesota** in St. Paul, the **Mayo Clinic** in Rochester, and **Minnesota Gastroenterology (MNGASTRO)** in Plymouth and St. Paul.

Mental Illness affects nearly 60 million Americans suffering from some form of the disease—from anxiety to depression to schizophrenia to eating disorders. In Minnesota, about 168,000 adults live with serious mental illness and about 56,000 children live with serious mental health conditions, according to the National Alliance on Mental Illness.

Currently, four clinical trials are recruiting patients in Minnesota. The trials are being conducted at the **University of Minnesota** in Minneapolis and at locations in Rochester.

Psoriasis and other skin disorders affect about 7.5 million Americans. In Minnesota and estimated 140,000 residents suffer from psoriasis, according to the Psoriasis Foundation.

Currently, 11 clinical trials are recruiting patients in Minnesota for skin disorders such as plaque psoriasis, atopic dermatitis and acne. The trials are being conducted at the **University of Minnesota** in Minneapolis, **Radiant Research** in Edina and the **Minnesota Clinical Study Center** in Fridley.

Respiratory Disorders, such as **asthma** and **chronic obstructive pulmonary disease (COPD)**, are the third leading cause of death in the United States and the fourth in Minnesota. Asthma affects more than 25 million Americans, including 7.1 million children under the age of 18. The toll is also severe in Minnesota—about 390,000 adults and children suffer from asthma, according to the Minnesota Department of Health. COPD, which includes chronic bronchitis and emphysema, affects more than 12.7 million Americans and in Minnesota 70,600 adults over the age of 45 have COPD.

Currently, 35 clinical trials of new respiratory disease medicines are recruiting patients in Minnesota. Trials are being conducted at the **University of Minnesota** and the **Minnesota Lung Center** in Minneapolis, the **Clinical Research Institute** in Plymouth, and the **Mayo Clinic** in Rochester.

Other diseases and medical conditions that are being targeted in Minnesota include:

- amyloidosis
- androgenic alopecia
- cataracts
- cervical dystonia
- endometriosis
- growth disorders
- hemophilia
- overactive bladder
- pigmented villonodular synovitis
- primary immunodeficiency diseases
- sarcopenia
- uveitis

Currently, there are 26 clinical trials recruiting patients for these diseases. The trials are underway at the **Mayo Clinic** in Rochester, the **Abbott Northwestern Hospital** and the **University of Minnesota** in Minneapolis, **Radiant Research** in Edina, **Prism Clinical Research** in St. Paul, and **Midwest Immunology Clinical and Infusion Center** in Plymouth.

Physicians and patients can find out about clinical trials being conducted all over the state in collaboration with local institutions by accessing ***www.clinicaltrials.gov****, a database sponsored by the National Institutes of Health. Information on clinical trials and medicines in development is also available on* ***www.phrma.org****, the website of the Pharmaceutical Research and Manufacturers of America (PhRMA). Click on Innovation,* Clinical Trials *and then* Research in Your Backyard.

New Generation Medicines in Development

Some of the medicines that have been tested in Minnesota are cutting-edge biotechnology drugs.

America's biopharmaceutical research companies are using biotechnology to develop hundreds of new medicines and vaccines today. And Minnesota is one of the states where this research and development work is being done.

Through biotechnology, new ways are being developed to not only more effectively treat disease, but also to predict and even prevent it. Biotechnology medicines are developed through biological processes using living cells or organisms, rather than traditional chemical synthesis, the mainstay of pharmaceutical development for decades.

Such novel treatments use a variety of new approaches to treat disease. For example, a monoclonal antibody is a laboratory-made version of the naturally occurring immune system protein that binds to and neutralizes foreign invaders. Interferons are proteins that interfere with the ability of a cell to reproduce.

Antisense drugs, meanwhile, are medicines that interfere with the communication process that tells a cell to produce an unwanted protein. In addition, nanotechnology is being used in biotechnology research to provide drug delivery systems, new treatments and diagnostics.

Some of the medicines in clinical testing at Minnesota hospitals and research centers feature these technologies.

For example:

- A genetically-modified virus-based vaccine to treat melanoma with clinical trials conducted at the **Hubert H. Humphrey Cancer Center** in Robbinsdale.
- A recombinant fusion protein to treat diabetic macular edema is being studied at the **Retina Center** in Minneapolis and the **Mayo Clinic** in Rochester.
- A therapeutic vaccine, designed to jump-start the immune system to fight disease, is in development for lung cancer and melanoma with clinical trials ongoing in **Fridley, Maplewood, Minneapolis, Rochester** and **St. Louis Park**.
- A monoclonal antibody in the pipeline that targets non-Hodgkin's lymphoma is in trials at the **Mayo Clinic** in Rochester

The biotechnology medicines and vaccines that are being developed today are helping to expand the frontiers of science and that could lead to more and better treatments for patients. In Minnesota, as in other states, this innovation is the result of a successful collaboration of biopharmaceutical companies and local research institutions.

Conclusion

Biopharmaceutical research companies' close collaboration with clinicians and research institutions in Minnesota benefits patients, the state's economy and the advancement of science and patient care. Clinical trials provide stimulating biopharmaceutical research work and a reliable source of revenue for the states' medical schools, hospitals and contract research organizations. And the medicines being tested are sometimes cutting-edge cell and protein treatments with the potential to be safer and more effective than older chemical compound drugs.

What's more, Minnesotans considering participation in clinical trials have a wide range of choices, including 419 tests of new medicines for the most chronic and most debilitating diseases.

The Drug Discovery, Development and Approval Process

It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

Clinical Trials

	Discovery/ Preclinical Testing	File IND at FDA	Phase I	Phase II	Phase III	File NDA/BLA at FDA	FDA	Phase IV
Years	**6.5**		**1.5**	**2**	**3.5**		**1.5**	
Test Population	Laboratory and animal studies		20 to 80 healthy volunteers	100 to 300 patient volunteers	1,000 to 3,000 patient volunteers		Review process/ approval	Additional post-marketing testing required by FDA
Purpose	Assess safety, biological activity and formulations		Determine safety and dosage	Evaluate effective-ness, look for side effects	Confirm effectiveness, monitor adverse reactions from long-term use			
Success Rate	5,000 compounds evaluated			5 enter trials			1 approved	

The Drug Development and Approval Process

The U.S. system of new drug approvals is perhaps the most rigorous in the world.

It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development. Only five in 5,000 compounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.

On average, it costs a company $1.2 billion, including the cost of failures, to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.

Once a new compound has been identified in the laboratory, medicines are usually developed as follows:

Preclinical Testing. A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evaluated for safety.

Investigational New Drug Application (IND). After completing preclinical testing, a company files an IND with the U.S. Food and Drug Administration (FDA) to begin to test the drug in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.

Clinical Trials, Phase I—Researchers test the drug in a small group of people, usually between 20 and 80 healthy adult volunteers, to evaluate its initial safety and tolerability profile, determine a safe dosage range, and identify potential side effects.

Clinical Trials, Phase II—The drug is given to volunteer patients, usually between 100 and 300, to see if it is effective, identify an optimal dose, and further evaluate its short-term safety.

Clinical Trials, Phase III—The drug is given to a larger, more diverse patient population, often involving between 1,000 and 3,000 patients (but sometime many more thousands), to generate statistically significant evidence to confirm its safety and effectiveness. They are the longest studies, and usually take place in multiple sites around the world.

New Drug Application (NDA)/Biologic License Application (BLA). Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more.

Approval. Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects.

Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. PhRMA member companies invested an estimated $48.5 billion in research and development in 2012.

The Good News – Many Clinical Trials are Still Recruiting

There are 419 clinical trials of new medicines recruiting in Minnesota. These trials target many of the chronic and debilitating diseases affecting Americans and Minnesotans.

Clinical Trials in Minnesota Communities

Location	Arth	Ca	Crd	Crohn's	Dia	Ep	ID	K/L	Mental	Psor	Resp	Other
Brooklyn Ctr	—	—	1	—	—	—	—	—	—	—	—	—
Chaska	2	—	2	1	—	—	—	—	—	—	—	1
Duluth	1	3	6	—	2	—	2	1	—	—	—	—
Eagan	10	—	—	—	1	—	—	—	—	—	1	1
Edina	3	6	5	—	1	—	2	—	—	1	5	5
Fridley	—	2	1	—	—	—	—	—	—	10	6	1
Golden Valley	—	—	—	—	—	4	—	—	—	—	—	—
Minneapolis	—	62	42	5	5	6	20	14	2	1	31	8
Plymouth	—	—	—	7	—	1	1	1	—	—	6	1
Rochester	2	77	15	16	—	4	2	14	1	—	12	5
St. Louis Park	—	21	3	—	—	1	—	—	—	—	—	—
St. Cloud	—	3	10	—	2	—	1	—	—	—	—	—
St. Paul	—	4	8	3	4	6	4	5	1	—	—	1

Source: www.clinicaltrials.gov
Note: Search criteria = Minnesota, United States; Phase 0, 1, 2, 3; industry only. Search performed 11/27/2013. See Appendix for detailed information about these clinical trials. ***Disease columns will not match totals in the Appendix because some clinical trials are recruiting in more than one city. This list of cities and towns is representative and not a complete list of where clinical trials are taking place in Minnesota.***

The Good News–Many Clinical Trials are Still Recruiting
(continued)

Arthritis—Institutions Conducting Clinical Trials

Mayo Clinic, Rochester
St. Paul Rheumatology, St. Paul

Cancer—Institutions Conducting Clinical Trials

Abbott Northwestern Hospital, Minneapolis
CentraCare St. Cloud Hospital, St. Cloud
Children's Hospital & Clinics of Minnesota, Minneapolis
Fairview Ridges Hospital, Burnsville
Fairview Southdale Hospital, Edina
Hennepin County Medical Center, Minneapolis
Hutchinson Area Health Care, Hutchinson
John Nasseff Neuroscience Institute, Minneapolis
Lakeview Hospital, Stillwater
Mayo Clinic, Rochester
Mercy Hospital, Coon Rapids
Minnesota Oncology Associates, Coon Rapids, St. Paul
Minnesota Oncology Hematology, Edina, Maplewood, Minneapolis, Woodbury
Minnesota VA Medical Center, Minneapolis
New Ulm Medical Center, New Ulm
North Memorial Hubert H. Humphrey Cancer Center, Robbinsdale
Park Nicollet Fravenshuh Cancer Center, St. Louis Park
Regions Hospital-Healtheast, St. Paul
Rice Memorial Hospital, Willmar
Ridgeview Medical Center, Waconia
Sanford Clinic North, Bemidgi
St. Francis Regional Medical Center, Shakopee
St. John's Hospital, Maplewood
St. Luke's Hospital Whiteside Institute for Clinical Research, Duluth
St. Mary's Hospital-Mayo Clinic, Rochester
Unity Hospital, Fridley
University of Minnesota, Minneapolis
University of Minnesota Children's Hospital, Minneapolis
Virginia Piper Cancer Institute-Abbott Northwestern Hospital, Minneapolis
Woodbury Clinic-CornerStone Medical Specialty Centre, Woodbury

Cardiovascular Disease—Institutions Conducting Clinical Trials

Abbott Northwestern Hospital, Minneapolis
CentraCare Heart and Vascular Center, St. Cloud
Cub Pharmacy, Rosemont
Goodrich Pharmacy, Fridley, St. Francis
Hennepin County Medical Center, Minneapolis
Kemper Drug, Elk River
MAPS Applied Research Center (MARC), Edina
Mayo Clinic, Rochester
Minneapolis Clinic of Neurology, Robbinsdale
Minneapolis Heart Institute Foundation, Minneapolis
Minneapolis VA Health Care System, Minneapolis
Minnesota Center for Obesity, Metabolism and Endocrinology (MNCOME), Eagan
Northfield Pharmacy, Northfield
Park Nicollet Institute/Methodist Hospital, St. Louis Park
Prism Clinical Research, St. Paul
Radiant Research, Edina
St. Joseph's Hospital-Healtheast, St. Paul
St. Mary's Hospital, Mayo Clinic, Rochester
United Heart and Vascular Center, St. Paul
University of Minnesota, Minneapolis

Crohn's Disease/Ulcerative Colitis—Institutions Conducting Clinical Trials

Mayo Clinic, Rochester
Minnesota Colon & Rectal Surgery Associates, Minneapolis
Minnesota Gastroenterology (MNGASTRO), Plymouth
University of Minnesota, Minneapolis

The Good News–Many Clinical Trials are Still Recruiting
(continued)

Diabetes—Institutions Conducting Clinical Trials

Children's Hospitals and Clinics of Minnesota, St. Paul
Mayo Clinic International Diabetes Center, Minneapolis
Minnesota Center for Obesity, Metabolism and Endocrinology (MNCOME), Eagan
Prism Clinical Research, St. Paul
Twin Cities Clinical Research/Prism Clinical Research, Brooklyn Center

Epilepsy/Neurologic Disorders—Institutions Conducting Clinical Trials

Clinical Research Institute, Minneapolis, Plymouth
Gilette Children's Specialty Healthcare, St. Paul
Hennepin County Medical Center/Berman Center for Research, Minneapolis
MAPS Applied Research Center (MARC), Edina
Mayo Clinic, Rochester
Minneapolis Clinic of Neurology, Golden Valley
Minnesota Epilepsy Group, St. Paul
Prism Clinical Research, St. Paul
University of Minnesota, Minneapolis

Infectious Diseases—Institutions Conducting Clinical Trials

Abbott Northwestern Hospital, Minneapolis
Hennepin County Medical Center, Minneapolis
Mayo Clinic, Rochester
Minnesota Gastroenterology (MNGASTRO), St. Paul
Minnesota VA Health Care System, Minneapolis
Prism Clinical Research, St. Paul
Radiant Research, Edina
University of Minnesota, Minneapolis

Kidney and Liver Disorders—Institutions Conducting Clinical Trials

Children's Hospitals and Clinics of Minnesota, St. Paul
DaVita Clinical Research, Minneapolis
Mayo Clinic, Rochester
Minnesota Gastroenterology (MNGASTRO), Plymouth, St. Paul
Prism Clinical Research, St. Paul
St. Mary's Medical Center, Duluth
Twin Cities Clinical Research/Prism Clinical Research, Brooklyn Center
University of Minnesota, Minneapolis

Mental Illness—Institutions Conducting Clinical Trials

University of Minnesota Medical Center, Minneapolis

Respiratory Diseases—Institutions Conducting Clinical Trials

Clinical Research Institute, Minneapolis, Plymouth
Mayo Clinic, Rochester
Minnesota Lung Center, Minneapolis
University of Minnesota, Minneapolis
University of Minnesota Children's Hospital, Minneapolis

Other Diseases—Institutions Conducting Clinical Trials

Abbott Northwestern Hospital, Minneapolis
Clinical Research Center, Plymouth
Frestedt Inc., Edina
Mayo Clinic, Rochester
Metro Urology, Woodbury
Midwest Immunology Clinic and Infusion Center, Plymouth
Minnesota Center for Obesity, Metabolism and Endocrinology (MNCOME), Eagan
Minnesota Diet Research Center (MDRC), Edina
Minnesota Eye Consultants, Bloomington
Prism Clinical Research, St. Paul
Radiant Research, Edina
Rehabilitation Consultants, Eagan
University of Minnesota, Minneapolis

Appendix

The clinical trials listed here involve tests that have not yet started recruiting patients or are just now seeking volunteers to participate. This information is potentially valuable to patients still seeking effective treatments for their chronic diseases. It provides a new therapeutic option to discuss with physicians.

Those interested in obtaining more information about certain trials can use the URL code listed for each test to log onto *www.clinicaltrials.gov*, the clinical tests database of the National Institutes of Health.

Asthma
(15 clinical trial recruiting)

Study 1:

Secukinumab Efficacy and Safety Study in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-TNFα Agents.

http://ClinicalTrials.gov/show/NCT01770379

Study 2:

A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy

http://ClinicalTrials.gov/show/NCT01606761

Study 3:

Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis

http://ClinicalTrials.gov/show/NCT01649375

Study 4:

A Study on the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous RoActemra/Actemra (Tocilizumab) With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis

http://ClinicalTrials.gov/show/NCT01855789

Study 5:

Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

http://ClinicalTrials.gov/show/NCT00413699

Study 6:

Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA

http://ClinicalTrials.gov/show/NCT01901900

Study 7:

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents.

http://ClinicalTrials.gov/show/NCT01350804

Study 8:

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

http://ClinicalTrials.gov/show/NCT01377012

Study 9:

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab (AIN457) in Patients of Active Psoriatic Arthritis (PsA)

http://ClinicalTrials.gov/show/NCT01752634

Study 10:

Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis

http://ClinicalTrials.gov/show/NCT01892436

Study 11:

Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis

http://ClinicalTrials.gov/show/NCT01640938

Study 12:

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

http://ClinicalTrials.gov/show/NCT01882439

Study 13:

A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy

http://ClinicalTrials.gov/show/NCT01604343

Study 14:

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Patients (DARWIN1)

http://ClinicalTrials.gov/show/NCT01888874

Study 15:

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

http://ClinicalTrials.gov/show/NCT01860976

Cancer
(154 clinical trials recruiting)

Study 1:

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

http://ClinicalTrials.gov/show/NCT01666444

Study 2:

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

http://ClinicalTrials.gov/show/NCT01321541

Study 3:

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

http://ClinicalTrials.gov/show/NCT01493505

Study 4:

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

http://ClinicalTrials.gov/show/NCT00940602

Study 5:

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

http://ClinicalTrials.gov/show/NCT01958021

Study 6:

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

http://ClinicalTrials.gov/show/NCT01353222

Study 7:

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

http://ClinicalTrials.gov/show/NCT01483027

Study 8:

A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

http://ClinicalTrials.gov/show/NCT01287741

Study 9:

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

http://ClinicalTrials.gov/show/NCT01763164

Study 10:

A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer

http://ClinicalTrials.gov/show/NCT01966471

Study 11:

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

http://ClinicalTrials.gov/show/NCT01582672

Study 12:

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

http://ClinicalTrials.gov/show/NCT01610284

Study 13:

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer

http://ClinicalTrials.gov/show/NCT01839487

Study 14:

Phase 1/2, Open-label, Dose-escalation Study of ISIS-STAT3Rx, Administered to Patients With Advanced Cancers

http://ClinicalTrials.gov/show/NCT01563302

Study 15:

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

http://ClinicalTrials.gov/show/NCT01632306

Study 16:

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

http://ClinicalTrials.gov/show/NCT01712217

Study 17:

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma

http://ClinicalTrials.gov/show/NCT01435720

Study 18:

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

http://ClinicalTrials.gov/show/NCT01297543

Study 19:

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

http://ClinicalTrials.gov/show/NCT01592045

Study 20:

Multiple Ascending Dose of BMS-911543

http://ClinicalTrials.gov/show/NCT01236352

Study 21:

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

http://ClinicalTrials.gov/show/NCT01874054

Study 22:

CNDO-109-AANK for AML in First Complete Remission (CR1)

http://ClinicalTrials.gov/show/NCT01520558

Study 23:

Safety and Tolerability of HSC835 in Patients Undergoing Single Umbilical Cord Blood Transplant

http://ClinicalTrials.gov/show/NCT01930162

Study 24:

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

http://ClinicalTrials.gov/show/NCT01101581

Study 25:

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

http://ClinicalTrials.gov/show/NCT01474681

Study 26:

Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell NHL

http://ClinicalTrials.gov/show/NCT01874288

Study 27:

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

http://ClinicalTrials.gov/show/NCT01295710

Study 28:

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

http://ClinicalTrials.gov/show/NCT01846611

Study 29:

A Phase I Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01794520

Study 30:

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

http://ClinicalTrials.gov/show/NCT01664923

Study 31:

Regorafenib as Adjuvant Therapy for Colorectal Cancer (CRC) With Resected Liver Metastases

http://ClinicalTrials.gov/show/NCT01939223

Study 32:

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

http://ClinicalTrials.gov/show/NCT01578239

Study 33:

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01478048

Study 34:

A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

http://ClinicalTrials.gov/show/NCT01262651

Study 35:

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

http://ClinicalTrials.gov/show/NCT01777152

Study 36:

A Study Evaluating BMN 673, a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation

http://ClinicalTrials.gov/show/NCT01945775

Study 37:

Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma

http://ClinicalTrials.gov/show/NCT01712490

Study 38:

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

http://ClinicalTrials.gov/show/NCT00925600

Study 39:

Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

http://ClinicalTrials.gov/show/NCT01325701

Study 40:

Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light

http://ClinicalTrials.gov/show/NCT01256203

Study 41:

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors

http://ClinicalTrials.gov/show/NCT01302405

Study 42:

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

http://ClinicalTrials.gov/show/NCT01453205

Study 43:

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

http://ClinicalTrials.gov/show/NCT01844505

Study 44:

A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment

http://ClinicalTrials.gov/show/NCT01801111

Study 45:

Study of Brentuximab Vedotin Combined With RCHOP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

http://ClinicalTrials.gov/show/NCT01925612

Study 46:

Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

http://ClinicalTrials.gov/show/NCT01905813

Study 47:

A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

http://ClinicalTrials.gov/show/NCT01968213

Study 48:

A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

http://ClinicalTrials.gov/show/NCT01351415

Study 49:

Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

http://ClinicalTrials.gov/show/NCT01857817

Study 50:

coBRIM: A Phase 3 Study Comparing GDC-0973 (Cobimetinib), a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

http://ClinicalTrials.gov/show/NCT01689519

Study 51:

A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

http://ClinicalTrials.gov/show/NCT01975519

Study 52:

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

http://ClinicalTrials.gov/show/NCT01748721

Study 53:

MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01850524

Study 54:

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

http://ClinicalTrials.gov/show/NCT01309126

Study 55:

Study of Cabozantinib (XL184) vs. Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

http://ClinicalTrials.gov/show/NCT01908426

Study 56:

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/ MK-3475-001)

http://ClinicalTrials.gov/show/NCT01295827

Study 57:

A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

http://ClinicalTrials.gov/show/NCT01740427

Study 58:

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

http://ClinicalTrials.gov/show/NCT01498328

Study 59:

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

http://ClinicalTrials.gov/show/NCT01593228

Study 60:

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01734928

Study 61:

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

http://ClinicalTrials.gov/show/NCT01584531

Study 62:

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

http://ClinicalTrials.gov/show/NCT01836432

Study 63:

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

http://ClinicalTrials.gov/show/NCT00979134

Study 64:

A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age

http://ClinicalTrials.gov/show/NCT01358734

Study 65:

A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations

http://ClinicalTrials.gov/show/NCT01336634

Study 66:

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

http://ClinicalTrials.gov/show/NCT01460134

Study 67:

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

http://ClinicalTrials.gov/show/NCT00790036

Study 68:

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

http://ClinicalTrials.gov/show/NCT00891137

Study 69:

Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

http://ClinicalTrials.gov/show/NCT01460537

Study 70:

Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)

http://ClinicalTrials.gov/show/NCT01451437

Study 71:

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01564537

Study 72:

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

http://ClinicalTrials.gov/show/NCT01928537

Study 73:

Brentuximab Vedotin in Patients With CD30-positive Non-lymphomatous Malignancies

http://ClinicalTrials.gov/show/NCT01461538

Study 74:

A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety

http://ClinicalTrials.gov/show/NCT01976143

Study 75:

A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

http://ClinicalTrials.gov/show/NCT01160744

Study 76:

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

http://ClinicalTrials.gov/show/NCT01483144

Study 77:

Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer

http://ClinicalTrials.gov/show/NCT01687244

Study 78:

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

http://ClinicalTrials.gov/show/NCT01695044

Study 79:

Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma

http://ClinicalTrials.gov/show/NCT01774344

Study 80:

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

http://ClinicalTrials.gov/show/NCT01891344

Study 81:

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

http://ClinicalTrials.gov/show/NCT01696045

Study 82:

A Study of LY2875358 in Patients With Advanced Cancer

http://ClinicalTrials.gov/show/NCT01287546

Study 83:

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

http://ClinicalTrials.gov/show/NCT01721746

Study 84:

A Study of Cabozantinib (XL184) vs. Everolimus in Subjects With Metastatic Renal Cell Carcinoma

http://ClinicalTrials.gov/show/NCT01865747

Study 85:

Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas

http://ClinicalTrials.gov/show/NCT01078649

Study 86:

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

http://ClinicalTrials.gov/show/NCT01170650

Study 87:

Phase II Phosphatidylinositol 3-Kinase (PI3K) Inhibitor in Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (NHL)

http://ClinicalTrials.gov/show/NCT01660451

Study 88:

A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants

http://ClinicalTrials.gov/show/NCT01900652

Study 89:

Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma

http://ClinicalTrials.gov/show/NCT01909453

Study 90:

Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to Imatinib

http://ClinicalTrials.gov/show/NCT01593254

Study 91:

A Study Using MABp1 To Increase Overall Survival In Patients With Colorectal Cancer And Weight Loss

http://ClinicalTrials.gov/show/NCT01767857

Study 92:

Panitumumab Pediatric Study

http://ClinicalTrials.gov/show/NCT00658658

Study 93:

Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

http://ClinicalTrials.gov/show/NCT01460160

Study 94:

Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

http://ClinicalTrials.gov/show/NCT01398462

Study 95:

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

http://ClinicalTrials.gov/show/NCT01482962

Study 96:

Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML

http://ClinicalTrials.gov/show/NCT01883362

Study 97:

Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

http://ClinicalTrials.gov/show/NCT01282463

Study 98:

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

http://ClinicalTrials.gov/show/NCT01433263

Study 99:

Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer

http://ClinicalTrials.gov/show/NCT01229865

Study 100:

Study of Minnelide™ in Patients With Advanced GI Tumors

http://ClinicalTrials.gov/show/NCT01927965

Study 101:

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

http://ClinicalTrials.gov/show/NCT01576666

Study 102:

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

http://ClinicalTrials.gov/show/NCT01421667

Study 103:

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

http://ClinicalTrials.gov/show/NCT00045968

Study 104:

BKM120 for Patients With PI3K-activated Tumors

http://ClinicalTrials.gov/show/NCT01833169

Study 105:

Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy

http://ClinicalTrials.gov/show/NCT01592370

Study 106:

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET)—Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ)

http://ClinicalTrials.gov/show/NCT01697072

Study 107:

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

http://ClinicalTrials.gov/show/NCT01772472

Study 108:

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

http://ClinicalTrials.gov/show/NCT01843374

Study 109:

Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)

http://ClinicalTrials.gov/show/NCT01721876

Study 110:

An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVENTM in Subjects With Cancer Who Also Have Impaired Renal Function

http://ClinicalTrials.gov/show/NCT01418677

Study 111:

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

http://ClinicalTrials.gov/show/NCT01764477

Study 112:

A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

http://ClinicalTrials.gov/show/NCT01991678

Study 113:

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

http://ClinicalTrials.gov/show/NCT01480479

Study 114:

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

http://ClinicalTrials.gov/show/NCT01308580

Study 115:

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

http://ClinicalTrials.gov/show/NCT01750580

Study 116:

Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

http://ClinicalTrials.gov/show/NCT01948180

Study 117:

Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

http://ClinicalTrials.gov/show/NCT01420783

Study 118:

Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

http://ClinicalTrials.gov/show/NCT01510184

Study 119:

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia

http://ClinicalTrials.gov/show/NCT01696084

Study 120:

Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy

http://ClinicalTrials.gov/show/NCT01287585

Study 121:

A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

http://ClinicalTrials.gov/show/NCT01774786

Study 122:

Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy

http://ClinicalTrials.gov/show/NCT01844986

Study 123:

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

http://ClinicalTrials.gov/show/NCT01440088

Study 124:

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01456689

Study 125:

A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

http://ClinicalTrials.gov/show/NCT01799889

Study 126:

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

http://ClinicalTrials.gov/show/NCT01322490

Study 127:

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

http://ClinicalTrials.gov/show/NCT01556490

Study 128:

A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01769391

Study 129:

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

http://ClinicalTrials.gov/show/NCT00680992

Study 130:

A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

http://ClinicalTrials.gov/show/NCT01469793

Study 131:

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

http://ClinicalTrials.gov/show/NCT01569295

Study 132:

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

http://ClinicalTrials.gov/show/NCT01566695

Study 133:

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

http://ClinicalTrials.gov/show/NCT01303796

Study 134:

A Study of Vismodegib With Surgery in Patients With Previously Untreated Basal Cell Carcinoma

http://ClinicalTrials.gov/show/NCT01898598

Study 135:

Clinical Study of PM01183 in Patients With Acute Leukemia

http://ClinicalTrials.gov/show/NCT01314599

Study 136:

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

http://ClinicalTrials.gov/show/NCT00790842

Study 137:

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

http://ClinicalTrials.gov/show/NCT00981799

Study 138:

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

http://ClinicalTrials.gov/show/NCT01696461

Study 139:

S0820, Adenoma and Second Primary Prevention Trial

http://ClinicalTrials.gov/show/NCT01349881

Study 140:

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

http://ClinicalTrials.gov/show/NCT01809691

Study 141:

A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas

http://ClinicalTrials.gov/show/NCT01782313

Study 142:

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

http://ClinicalTrials.gov/show/NCT01321346

Study 143:

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

http://ClinicalTrials.gov/show/NCT01497444

Study 144:

Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma

http://ClinicalTrials.gov/show/NCT01431209

Study 145:

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

http://ClinicalTrials.gov/show/NCT01797120

Study 146:

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

http://ClinicalTrials.gov/show/NCT01429025

Study 147:

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

http://ClinicalTrials.gov/show/NCT01681433

Study 148:

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

http://ClinicalTrials.gov/show/NCT01008150

Study 149:

Accelerating Gastrointestinal Recovery

http://ClinicalTrials.gov/show/NCT01704651

Study 150:

Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

http://ClinicalTrials.gov/show/NCT01772953

Study 151:

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission

http://ClinicalTrials.gov/show/NCT01639456

Study 152:

Everolimus Versus Placebo in Head and Neck Cancer

http://ClinicalTrials.gov/show/NCT01111058

Study 153:

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

http://ClinicalTrials.gov/show/NCT01330966

Study 154:

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

http://ClinicalTrials.gov/show/NCT01506596

Cardiovascular Disease

(58 clinical trials recruiting)

Study 1:

Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727) (ODYSSEY Outcomes)

http://ClinicalTrials.gov/show/NCT01663402

Study 2:

Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure

http://ClinicalTrials.gov/show/NCT01661634

Study 3:

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

http://ClinicalTrials.gov/show/NCT01920711

Study 4:

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

http://ClinicalTrials.gov/show/NCT01101035

Study 5:

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

http://ClinicalTrials.gov/show/NCT01327846

Study 6:

INcrease Of VAgal TonE in CHF

http://ClinicalTrials.gov/show/NCT01303718

Study 7:

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

http://ClinicalTrials.gov/show/NCT01764633

Study 8:

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

http://ClinicalTrials.gov/show/NCT01732822

Study 9:

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

http://ClinicalTrials.gov/show/NCT01609582

Study 10:

A Study of Evacetrapib in High-Risk Vascular Disease

http://ClinicalTrials.gov/show/NCT01687998

Study 11:

Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

http://ClinicalTrials.gov/show/NCT01508910

Study 12:

The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves

http://ClinicalTrials.gov/show/NCT01314313

Study 13:

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

http://ClinicalTrials.gov/show/NCT01813422

Study 14:

Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia

http://ClinicalTrials.gov/show/NCT01426425

Study 15:

Actual Use Trial of Atorvastatin Calcium 10 mg

http://ClinicalTrials.gov/show/NCT01964326

Study 16:

AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction

http://ClinicalTrials.gov/show/NCT01495364

Study 17:

Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

http://ClinicalTrials.gov/show/NCT01876368

Study 18:

Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure

http://ClinicalTrials.gov/show/NCT01112579

Study 19:

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

http://ClinicalTrials.gov/show/NCT01457781

Study 20:

An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

http://ClinicalTrials.gov/show/NCT01670981

Study 21:

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

http://ClinicalTrials.gov/show/NCT01639495

Study 22:

Gene Therapy for the Treatment of Chronic Stable Angina

http://ClinicalTrials.gov/show/NCT01002495

Study 23:

Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration

http://ClinicalTrials.gov/show/NCT01458405

Study 24:

A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke

http://ClinicalTrials.gov/show/NCT01584609

Study 25:

Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction

http://ClinicalTrials.gov/show/NCT00555828

Study 26:

Study to Assess the Effects of Intravenous Bendavia in Patients Undergoing Percutaneous Transluminal Angioplasty of the Renal Artery (PTRA)

http://ClinicalTrials.gov/show/NCT01755858

Study 27:

The eMESH 1 Feasibility Study

http://ClinicalTrials.gov/show/NCT01676376

Study 28:

COSMIC-HF—Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

http://ClinicalTrials.gov/show/NCT01786512

Study 29:

The Medtronic CoreValve™ Evolut R™ Clinical Study

http://ClinicalTrials.gov/show/NCT01876420

Study 30:

Oral Rivaroxaban in Children With Venous Thrombosis

http://ClinicalTrials.gov/show/NCT01684423

Study 31:

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

http://ClinicalTrials.gov/show/NCT01926782

Study 32:

Study to Examine the Effects of MultiStem in Ischemic Stroke

http://ClinicalTrials.gov/show/NCT01436487

Study 33:

VIVID—Valvular and Ventricular Improvement Via iCoapsys Delivery—Feasibility Study

http://ClinicalTrials.gov/show/NCT00512005

Study 34:

The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects

http://ClinicalTrials.gov/show/NCT01893515

Study 35:

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

http://ClinicalTrials.gov/show/NCT01583218

Study 36:

Open Label Study of Long Term Evaluation Against LDL-C Trial-2

http://ClinicalTrials.gov/show/NCT01854918

Study 37:

Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

http://ClinicalTrials.gov/show/NCT01890421

Study 38:

ST Monitoring to Detect Acute Coronary Syndrome Events in Implantable Cardioverter Defibrillator Patients

http://ClinicalTrials.gov/show/NCT01424722

Study 39:

Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia

http://ClinicalTrials.gov/show/NCT01556022

Study 40:

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

http://ClinicalTrials.gov/show/NCT01475825

Study 41:

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

http://ClinicalTrials.gov/show/NCT01273337

Study 42:

A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

http://ClinicalTrials.gov/show/NCT01618669

Study 43:

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

http://ClinicalTrials.gov/show/NCT01729871

Study 44:

Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

http://ClinicalTrials.gov/show/NCT01870778

Study 45:

Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients

http://ClinicalTrials.gov/show/NCT01922089

Study 46:

Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack

http://ClinicalTrials.gov/show/NCT01539590

Study 47:

Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication (IC)

http://ClinicalTrials.gov/show/NCT01679990

Study 48:

nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

http://ClinicalTrials.gov/show/NCT01824394

Study 49:

C-Pulse® System: A Heart Assist Device Clinical Study

http://ClinicalTrials.gov/show/NCT01740596

Study 50:

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

http://ClinicalTrials.gov/show/NCT00790335

Study 51:

The Evaluation of VAD InterVEntion Before Inotropic Therapy

http://ClinicalTrials.gov/show/NCT01369407

Study 52:

Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III

http://ClinicalTrials.gov/show/NCT01067339

Study 53:

Insulin Resistance Intervention After Stroke Trial

http://ClinicalTrials.gov/show/NCT00091949

Study 54:

A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

http://ClinicalTrials.gov/show/NCT01522950

Study 55:

Patients With Intermittent Claudication Injected With ALDH Bright Cells

http://ClinicalTrials.gov/show/NCT01774097

Study 56:

Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Patients

http://ClinicalTrials.gov/show/NCT01626079

Study 57:

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Giant Cell Arteritis

http://ClinicalTrials.gov/show/NCT01791153

Study 58:

Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

http://ClinicalTrials.gov/show/NCT01920594

Crohn's Disease/Ulcerative Colitis/Gastrointestinal Diseases

(24 clinical trials recruiting)

Study 1:

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

http://ClinicalTrials.gov/show/NCT01276509

Study 2:

A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

http://ClinicalTrials.gov/show/NCT01620255

Study 3:

A Study To Monitor Long-Term Treatment With PF-00547659

http://ClinicalTrials.gov/show/NCT01298492

Study 4:

Safety Study of Entocort for Children With Crohn's Disease

http://ClinicalTrials.gov/show/NCT01444092

Study 5:

Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)

http://ClinicalTrials.gov/show/NCT01890837

Study 6:

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

http://ClinicalTrials.gov/show/NCT01642602

Study 7:

Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic Constipation

http://ClinicalTrials.gov/show/NCT01781104

Study 8:

Prospective, Multicenter Trial to Investigate the Safety and Efficacy of Percutaneous Tibial Nerve Stimulation for the Treatment of Fecal Incontinence

http://ClinicalTrials.gov/show/NCT01666405

Study 9:

Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis

http://ClinicalTrials.gov/show/NCT01294410

Study 10:

Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis

http://ClinicalTrials.gov/show/NCT01470612

Study 11:

OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension

http://ClinicalTrials.gov/show/NCT01642212

Study 12:

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents

http://ClinicalTrials.gov/show/NCT01642615

Study 13:

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

http://ClinicalTrials.gov/show/NCT01722318

Study 14:

Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients

http://ClinicalTrials.gov/show/NCT01917630

Study 15:

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

http://ClinicalTrials.gov/show/NCT01369342

Study 16:

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

http://ClinicalTrials.gov/show/NCT01453946

Study 17:

A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis

http://ClinicalTrials.gov/show/NCT01458951

Study 18:

Intra-patient Dose Escalation Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide (SOM230) Subcutaneous (s.c.) Followed by Pasireotide LAR in Patients With Dumping Syndrome

http://ClinicalTrials.gov/show/NCT01637272

Study 19:

A Study Of Oral CP-690550 As A Maintenance Therapy For Ulcerative Colitis

http://ClinicalTrials.gov/show/NCT01458574

Study 20:

A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis

http://ClinicalTrials.gov/show/NCT01900574

Study 21:

A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation

http://ClinicalTrials.gov/show/NCT01523184

Study 22:

Trial of Montelukast in Eosinophilic Esophagitis

http://ClinicalTrials.gov/show/NCT00511316

Study 23:

Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis

http://ClinicalTrials.gov/show/NCT01953354

Study 24:

A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome

http://ClinicalTrials.gov/show/NCT00977197

Diabetes
(10 clinical trials recruiting)

Study 1:

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

http://ClinicalTrials.gov/show/NCT01730534

Study 2:

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01144338

Study 3:

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

http://ClinicalTrials.gov/show/NCT01609582

Study 4:

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

http://ClinicalTrials.gov/show/NCT01831765

Study 5:

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

http://ClinicalTrials.gov/show/NCT01434186

Study 6:

Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)

http://ClinicalTrials.gov/show/NCT01948986

Study 7:

Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01835730

Study 8:

Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes

http://ClinicalTrials.gov/show/NCT01824264

Study 9:

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT01794143

Study 10:

Effectiveness and Safety of Intranasal Glucagon for Treatment of Hypoglycemia in Adults

http://ClinicalTrials.gov/show/NCT01994746

Epilepsy/Neurological Disorders
(21 clinical trials recruiting)

Study 1:

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters

http://ClinicalTrials.gov/show/NCT01390220

Study 2:

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

http://ClinicalTrials.gov/show/NCT01665144

Study 3:

A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy

http://ClinicalTrials.gov/show/NCT01926444

Study 4:

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

http://ClinicalTrials.gov/show/NCT01968031

Study 5:

A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

http://ClinicalTrials.gov/show/NCT01262651

Study 6:

Efficacy and Safety of ISIS-TTRRx in Familial Amyloid Polyneuropathy

http://ClinicalTrials.gov/show/NCT01737398

Study 7:

Phase 2 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures, With Long-term Open-label Extension

http://ClinicalTrials.gov/show/NCT01963208

Study 8:

Dysport® Pediatric Lower Limb Spasticity Study

http://ClinicalTrials.gov/show/NCT01249417

Study 9:

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

http://ClinicalTrials.gov/show/NCT01261325

Study 10:

A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

http://ClinicalTrials.gov/show/NCT00938431

Study 11:

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

http://ClinicalTrials.gov/show/NCT01529034

Study 12:

A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures

http://ClinicalTrials.gov/show/NCT01393743

Study 13:

Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump

http://ClinicalTrials.gov/show/NCT01520545

Study 14:

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

http://ClinicalTrials.gov/show/NCT01713946

Study 15:

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

http://ClinicalTrials.gov/show/NCT01709149

Study 16:

A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis

http://ClinicalTrials.gov/show/NCT01906658

Study 17:

A Phase 2 Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

http://ClinicalTrials.gov/show/NCT01952574

Study 18:

Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy

http://ClinicalTrials.gov/show/NCT01826487

Study 19:

Riluzole in Spinal Cord Injury Study

http://ClinicalTrials.gov/show/NCT01597518

Study 20:

Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease

http://ClinicalTrials.gov/show/NCT01588314

Study 21:

ACTH in Progressive Forms of MS

http://ClinicalTrials.gov/show/NCT01950234

Infectious Diseases

(31 clinical trials recruiting)

Study 1:

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

http://ClinicalTrials.gov/show/NCT01595438

Study 2:

Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections

http://ClinicalTrials.gov/show/NCT01499277

Study 3:

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM3)

http://ClinicalTrials.gov/show/NCT01254630

Study 4:

A Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

http://ClinicalTrials.gov/show/NCT01598311

Study 5:

Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

http://ClinicalTrials.gov/show/NCT01938430

Study 6:

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

http://ClinicalTrials.gov/show/NCT01797445

Study 7:

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

http://ClinicalTrials.gov/show/NCT00413218

Study 8:

Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores

http://ClinicalTrials.gov/show/NCT01985321

Study 9:

A Study Comparing Ceftazidime-Avibactam+ Metronidazole Versus Meropenem in Adults With Complicated Intra-abdominal Infections

http://ClinicalTrials.gov/show/NCT01500239

Study 10:

Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

http://ClinicalTrials.gov/show/NCT01597505

Study 11:

A Pharmacokinetic/Pharmacodynamic Study of Tamiflu (Oseltamivir) in Immunocompromised Children With Confirmed Influenza Infection

http://ClinicalTrials.gov/show/NCT01715909

Study 12:

Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

http://ClinicalTrials.gov/show/NCT01610414

Study 13:

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

http://ClinicalTrials.gov/show/NCT01925417

Study 14:

Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine

http://ClinicalTrials.gov/show/NCT01995617

Study 15:

Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003 AM4)

http://ClinicalTrials.gov/show/NCT01505634

Study 16:

Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects

http://ClinicalTrials.gov/show/NCT01815736

Study 17:

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

http://ClinicalTrials.gov/show/NCT01625338

Study 18:

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

http://ClinicalTrials.gov/show/NCT01967940

Study 19:

Sofosbuvir+RBV for 16 or 24 Weeks and Sofosbuvir+PEG+RBV for 12 Weeks in Subjects With Genotype 2 or 3 Chronic HCV Infection

http://ClinicalTrials.gov/show/NCT01962441

Study 20:

Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

http://ClinicalTrials.gov/show/NCT01691248

Study 21:

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

http://ClinicalTrials.gov/show/NCT01968551

Study 22:

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

http://ClinicalTrials.gov/show/NCT01830855

Study 23:

Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects

http://ClinicalTrials.gov/show/NCT01827657

Study 24:

Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004 AM2)

http://ClinicalTrials.gov/show/NCT01506271

Study 25:

Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients

http://ClinicalTrials.gov/show/NCT01611974

Study 26:

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

http://ClinicalTrials.gov/show/NCT01992276

Study 27:

Study of Intravenous Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam in Ventilator Associated Pneumonia

http://ClinicalTrials.gov/show/NCT01853982

Study 28:

Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older

http://ClinicalTrials.gov/show/NCT01992094

Study 29:

Open-label Safety Study of Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

http://ClinicalTrials.gov/show/NCT01818596

Study 30:

A Pilot Trial of Safety and Efficacy of Telaprevir +Peginterferon +Ribavirin +Vitamin D3 v. Telaprevir +Peginterferon +Ribavirin Among Treatment-naive Veterans With Genotype 1 Hepatitis C Virus

http://ClinicalTrials.gov/show/NCT01890772

Study 31:

Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV

http://ClinicalTrials.gov/show/NCT01852942

Kidney and Liver Disorders
(32 clinical trials recruiting)

Study 1:

Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study

http://ClinicalTrials.gov/show/NCT00628498

Study 2:

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

http://ClinicalTrials.gov/show/NCT01904058

Study 3:

A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

http://ClinicalTrials.gov/show/NCT01559363

Study 4:

Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

http://ClinicalTrials.gov/show/NCT01958970

Study 5:

A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD

http://ClinicalTrials.gov/show/NCT01873534

Study 6:

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

http://ClinicalTrials.gov/show/NCT01764854

Study 7:

Study of IDN-6556 in Patients With Severe AH and Contradictions to Steroid Therapy

http://ClinicalTrials.gov/show/NCT01912404

Study 8:

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis

http://ClinicalTrials.gov/show/NCT01865812

Study 9:

Study Assessing the Behavior of Delayed-Release Metformin in Subjects With Kidney Dysfunction

http://ClinicalTrials.gov/show/NCT01658514

Study 10:

Contrast Media Reduction and Removal in Patients With CKD (PRESERV)

http://ClinicalTrials.gov/show/NCT01168024

Study 11:

Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure

http://ClinicalTrials.gov/show/NCT01471028

Study 12:

A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects

http://ClinicalTrials.gov/show/NCT01602328

Study 13:

Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants

http://ClinicalTrials.gov/show/NCT01888432

Study 14:

Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Subjects With Primary Sclerosing Cholangitis (PSC)

http://ClinicalTrials.gov/show/NCT01672853

Study 15:

Anti-Tweak in Lupus Nephritis Patients

http://ClinicalTrials.gov/show/NCT01499355

Study 16:

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

http://ClinicalTrials.gov/show/NCT01971164

Study 17:

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

http://ClinicalTrials.gov/show/NCT01777165

Study 18:

Simtuzumab (GS-6624) in the Treatment of Cirrhosis Due to NASH

http://ClinicalTrials.gov/show/NCT01672879

Study 19:

A Study of LY2928057 in Hemodialysis Participants

http://ClinicalTrials.gov/show/NCT01991483

Study 20:

Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients

http://ClinicalTrials.gov/show/NCT01598987

Study 21:

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

http://ClinicalTrials.gov/show/NCT01978587

Study 22:

BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

http://ClinicalTrials.gov/show/NCT01930890

Study 23:

Calcineurin Inhibitor Sparing After Kidney Transplantation

http://ClinicalTrials.gov/show/NCT01062555

Study 24:

Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant

http://ClinicalTrials.gov/show/NCT01106027

Study 25:

Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation

http://ClinicalTrials.gov/show/NCT01095887

Study 26:

Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)

http://ClinicalTrials.gov/show/NCT01893658

Study 27:

Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis

http://ClinicalTrials.gov/show/NCT01968382

Study 28:

Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males

http://ClinicalTrials.gov/show/NCT01835561

Study 29:

A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)

http://ClinicalTrials.gov/show/NCT01665391

Study 30:

Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

http://ClinicalTrials.gov/show/NCT01399593

Study 31:

Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)

http://ClinicalTrials.gov/show/NCT00955149

Study 32:

Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment

http://ClinicalTrials.gov/show/NCT01406340

Mental Illnesses
(4 clinical trials recruiting)

Study 1:

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

http://ClinicalTrials.gov/show/NCT01735630

Study 2:

Open Label Extension in Adults With Binge Eating Disorder (BED)

http://ClinicalTrials.gov/show/NCT01657019

Study 3:

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive-Compulsive Disorder

http://ClinicalTrials.gov/show/NCT01674361

Study 4:

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

http://ClinicalTrials.gov/show/NCT01626378

Psoriasis/Skin Disorders
(11 clinical trials recruiting)

Study 1:

Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis

http://ClinicalTrials.gov/show/NCT01873677

Study 2:

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis

http://ClinicalTrials.gov/show/NCT01871402

Study 3:

Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

http://ClinicalTrials.gov/show/NCT01708603

Study 4:

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)

http://ClinicalTrials.gov/show/NCT01722331

Study 5:

Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris

http://ClinicalTrials.gov/show/NCT01769235

Study 6:

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

http://ClinicalTrials.gov/show/NCT01163253

Study 7:

An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis

http://ClinicalTrials.gov/show/NCT01826461

Study 8:

Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

http://ClinicalTrials.gov/show/NCT01568489

Study 9:

Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis

http://ClinicalTrials.gov/show/NCT01908595

Study 10:

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

http://ClinicalTrials.gov/show/NCT01938599

Study 11:

Use of Botulinum Toxin to Treat Psoriasis

http://ClinicalTrials.gov/show/NCT00816517

Respiratory Disorders
(35 clinical trials recruiting)

Study 1:

Study to Evaluate the Effect of Fluticasone Furoate/ Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

http://ClinicalTrials.gov/show/NCT01313676

Study 2:

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate/Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

http://ClinicalTrials.gov/show/NCT01727141

Study 3:

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 1)

http://ClinicalTrials.gov/show/NCT01854645

Study 4:

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

http://ClinicalTrials.gov/show/NCT01970878

Study 5:

Long Term Safety Study of NVA237 vs. QAB149 in COPD Patients

http://ClinicalTrials.gov/show/NCT01697696

Study 6:

A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)

http://ClinicalTrials.gov/show/NCT01769196

Study 7:

Nintedanib Twice Daily vs. Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

http://ClinicalTrials.gov/show/NCT01979952

Study 8:

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

http://ClinicalTrials.gov/show/NCT01854658

Study 9:

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB in Patients With COPD Who Have Moderate to Severe Airflow Limitation

http://ClinicalTrials.gov/show/NCT01682863

Study 10:

NVA237 BID Versus Placebo Twelve-week Efficacy Study

http://ClinicalTrials.gov/show/NCT01715298

Study 11:

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

http://ClinicalTrials.gov/show/NCT01854047

Study 12:

Apnex Clinical Study of the Hypoglossal Nerve Stimulation (HGNS®) System to Treat Obstructive Sleep Apnea

http://ClinicalTrials.gov/show/NCT01446601

Study 13:

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

http://ClinicalTrials.gov/show/NCT01842607

Study 14:

Evaluate Safety of T/I on Diabetic Subjects With Mild Obstructive Pulmonary Disease

http://ClinicalTrials.gov/show/NCT00642616

Study 15:

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

http://ClinicalTrials.gov/show/NCT01766817

Study 16:

A Study to Evaluate Efficacy and Safety of ADC3680 in Subjects With Inadequately-Controlled Asthma

http://ClinicalTrials.gov/show/NCT01730027

Study 17:

An Efficacy and Safety Study of Fluticasone Furoate/ Vilanterol (FF/VI) 200/25 Microgram (Mcg), FF/VI 100/25 Mcg, and FF 100 Mcg in Adults and Adolescents With Persistent Asthma

http://ClinicalTrials.gov/show/NCT01686633

Study 18:

International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation (INSPIRE)

http://ClinicalTrials.gov/show/NCT01630434

Study 19:

Arikace® for Nontuberculous Mycobacteria

http://ClinicalTrials.gov/show/NCT01315236

Study 20:

Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment

http://ClinicalTrials.gov/show/NCT01695343

Study 21:

Efficacy and Safety of QGE031 versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma

http://ClinicalTrials.gov/show/NCT01716754

Study 22:

A Study of Lebrikizumab in Patients With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication

http://ClinicalTrials.gov/show/NCT01868061

Study 23:

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

http://ClinicalTrials.gov/show/NCT01629667

Study 24:

A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)

http://ClinicalTrials.gov/show/NCT01502371

Study 25:

A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients

http://ClinicalTrials.gov/show/NCT01836471

Study 26:

Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

http://ClinicalTrials.gov/show/NCT01746784

Study 27:

A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis

http://ClinicalTrials.gov/show/NCT01872689

Study 28:

Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study

http://ClinicalTrials.gov/show/NCT01608490

Study 29:

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

http://ClinicalTrials.gov/show/NCT01707290

Study 30:

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Inadequately Controlled Asthma Subjects With High Bronchodilator Reversibility

http://ClinicalTrials.gov/show/NCT01902290

Study 31:

Testing the Feasibility of Patient Controlled Sedation for Ventilated ICU Patients

http://ClinicalTrials.gov/show/NCT01606852

Study 32:

Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis

http://ClinicalTrials.gov/show/NCT01859390

Study 33:

Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

http://ClinicalTrials.gov/show/NCT01700192

Study 34:

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

http://ClinicalTrials.gov/show/NCT01915823

Study 35:

Phase III Cat-PAD Study

http://ClinicalTrials.gov/show/NCT01620762

Other Diseases
(26 clinical trials recruiting)

Study 1:

Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

http://ClinicalTrials.gov/show/NCT01868516

Study 2:

Phase 2/3 Study of IGSC, 20% in Primary Immunodeficiency Diseases (PIDD)

http://ClinicalTrials.gov/show/NCT01218438

Study 3:

Versartis Trial in Children to Assess Long-Acting Growth Hormone

http://ClinicalTrials.gov/show/NCT01718041

Study 4:

Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia

http://ClinicalTrials.gov/show/NCT01963598

Study 5:

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076 AM1)

http://ClinicalTrials.gov/show/NCT01803607

Study 6:

A Randomised Placebo-Controlled Study Evaluating the Efficacy and Safety of DYSPORT Using 2mL Dilution in Adults With Cervical Dystonia (CD)

http://ClinicalTrials.gov/show/NCT01753310

Study 7:

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

http://ClinicalTrials.gov/show/NCT01904721

Study 8:

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

http://ClinicalTrials.gov/show/NCT01620528

Study 9:

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries

http://ClinicalTrials.gov/show/NCT01731938

Study 10:

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

http://ClinicalTrials.gov/show/NCT01643850

Study 11:

Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders

http://ClinicalTrials.gov/show/NCT01195753

Study 12:

Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder

http://ClinicalTrials.gov/show/NCT01607658

Study 13:

Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

http://ClinicalTrials.gov/show/NCT01659658

Study 14:

Phase I, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

http://ClinicalTrials.gov/show/NCT01707264

Study 15:

Pivotal Study of the LVIS (Low Profile Visualized Intraluminal Support)

http://ClinicalTrials.gov/show/NCT01793792

Study 16:

Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F in Healthy Postmenopausal Women

http://ClinicalTrials.gov/show/NCT01721993

Study 17:

Compassionate Use of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES)

http://ClinicalTrials.gov/show/NCT00244686

Study 18:

Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B

http://ClinicalTrials.gov/show/NCT01687608

Study 19:

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A

http://ClinicalTrials.gov/show/NCT01731600

Study 20:

Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery

http://ClinicalTrials.gov/show/NCT01365546

Study 21:

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock

http://ClinicalTrials.gov/show/NCT01046669

Study 22:

Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects

http://ClinicalTrials.gov/show/NCT01860612

Study 23:

Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater

http://ClinicalTrials.gov/show/NCT00359632

Study 24:

Study Assessing Double-masked Uveitis Treatment

http://ClinicalTrials.gov/show/NCT01358266

Study 25:

Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery

http://ClinicalTrials.gov/show/NCT01461291

Study 26:

Safety and Effectiveness of Wavefront-guided LASIK for the Correction of Mixed Astigmatism

http://ClinicalTrials.gov/show/NCT01675492

PhRMA
RESEARCH • PROGRESS • HOPE

Pharmaceutical Research and Manufacturers of America
950 F Street, NW, Washington, DC 20004
www.phrma.org